Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cue Biopharma, Inc.CUE · Entity 6301 | Director | January 06, 2020 | January 06, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cue Biopharma, Inc.
Report date January 06, 2020 · Filed January 06, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.31 · Expires 2030-01-02 | Direct | 8,000 |
Reported balance
After 2020-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-01-02 · Grant · Acquired 8,000 · Balance 8,000 F1: Represents a stock option award granted on January 2, 2020 pursuant to the Issuer's Non-Employee Director Compensation Policy. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a stock option award granted on January 2, 2020 pursuant to the Issuer's Non-Employee Director Compensation Policy.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2020 Filed Jan 6, 2020 17:58 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $16.31 | $0.00 |
DisclosureSEC source: 0001209191-20-002063 · doc4.xml · derivative · entry 1 MCKNIGHT STEVEN L · CIK 0001182470 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2030-01-02 F1 · shares: Represents a stock option award granted on January 2, 2020 pursuant to the Issuer's Non-Employee Director Compensation Policy. Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 18:39 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $5.16 | $0.00 |
DisclosureSEC source: 0001209191-19-001332 · doc4.xml · derivative · entry 1 MCKNIGHT STEVEN L · CIK 0001182470 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2026-01-02 Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 17:37 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Exercise / conversionStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $14.24 | $0.00 |
DisclosureSEC source: 0001209191-18-037817 · doc4.xml · derivative · entry 1 MCKNIGHT STEVEN L · CIK 0001182470 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2025-06-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.